Trial Profile
Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole (Primary) ; Voriconazole (Primary)
- Indications Bacterial infections; Mycoses
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 21 May 2020 Status changed from active, no longer recruiting to completed.
- 10 Sep 2019 Planned End Date changed from 1 Feb 2021 to 1 Apr 2020.
- 10 Sep 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Apr 2020.